Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands									1 Months Ended															7 Months Ended	12 Months Ended
	Dec. 13, 2019 shares	Jul. 18, 2019 USD ($) shares	May 19, 2019	May 15, 2019	May 14, 2019 shares	May 07, 2019 shares	Apr. 04, 2018	Dec. 11, 2017	Dec. 20, 2019	Aug. 20, 2019 USD ($) shares	Apr. 29, 2019 shares	Apr. 18, 2019	Mar. 31, 2019 shares	Mar. 31, 2019	Mar. 31, 2019 shares	Mar. 02, 2019	Oct. 22, 2018 $ / shares	Oct. 22, 2018 USD ($) $ / shares shares	Jul. 31, 2018 USD ($) shares	Jun. 30, 2018 USD ($)	Apr. 30, 2018 USD ($)	Feb. 22, 2018	Feb. 19, 2018	Aug. 15, 2018	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares ₪ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2019 ₪ / shares	Oct. 15, 2019 shares	Aug. 15, 2019 shares	Jul. 31, 2019 shares	Mar. 01, 2019 USD ($)	Mar. 01, 2019 ₪ / shares	Feb. 28, 2018 shares
Warrants remain outstanding																																		788,658
Aggregate exercise price of warrants | $																											$ 1,145
Common stock shares issued																									15,873,128	15,873,128	8,957,550
Issued shares of common stock						336,000					336,000		60,000
Future investment exercised | $																									$ 71	$ 71
Common stock value issued for services | $		$ 3								$ 18																	$ 54
Common stock shares issued for services	337	6,945								45,000																	55,000
Registration statement, description																									The Company filed an amendment to the S-1 Registration Statement, for the purpose of registering (i) 922,330 shares of Common Stock that were outstanding as of that date; and (ii) 338,945 shares of Common Stock which are issuable upon conversion of the 2016 Loan and/or the 2017 Loan. On July 12, 2018, the S-1 Registration Statement was declared effective by the SEC.
Purchase agreement, description									The Company entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor. Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27 per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock. The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public announcement of positive clinical data results for LO2A.									The Company granted to the investors thereunder, for a period of three years from the closing date of the Purchase Agreement, a right of participation of up to an aggregate of 35% in any subsequent offering of the Company, subject to certain exceptions.
Warrant term, description																		The Series A Warrants have a term of 5 years from issuance, and the Series B Warrants have a term that expires 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) has occurred, the expiration date of the Series B Warrants will be extended by one day.
Unrecognized compensation cost | $																									$ 117	$ 117
Trading activities, description																		During the period commencing upon execution of the Purchase Agreement, and expiring on the trading day immediately following the date that the Company has raised, beginning after the issuance date of the Warrants, at least $10,000 in gross proceeds from the issuance of the Company's securities, the Company issues or sells Common Stock (or securities convertible into or exercisable into Common Stock) at a purchase price (or conversion or exercise price, as applicable) lower than the exercise price of the Warrants, than the exercise price of the Warrants will be reduced to such lower price, subject to certain exceptions.
Warrant exercise price | ₪ / shares																										$ 0.16
Finance expense | $																									$ 252
Placement ageny agreement, description																		The Company paid ThinkEquity a fee equal to 8% of the gross proceeds, excluding proceeds received from certain investors for its services as placement agent, and issued to ThinkEquity or its designees warrants to purchase 267,000 shares of Common Stock (equal to 6% of the shares of Common Stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)) (the "Placement Agent Warrants").
Placement agent warrants, description																		The Placement Agent Warrants have an exercise price of $1.00 per share and have the same terms as the Series A Warrants issued to the investors under the Purchase Agreement. The Company also paid to ThinkEquity a non-accountable expense allowance of $30 and reimbursed ThinkEquity for its legal expenses in connection with the offering in the amount of $50. The Company granted to ThinkEquity a right of first refusal for a period of nine months following the closing of the offering, to act as sole financial advisor, sole investment banker, sole book-runner, and/or sole placement agent, for each and every future public and private equity and debt offering of the Company during such period, on terms and conditions customary to ThinkEquity. The Company also paid Mesodi Consultation & Investments, Ltd. ("Mesodi") a fee of $89 and issued to Mesodi warrants (the "Mesodi Warrants") to purchase 89,000 shares of Common Stock. The Mesodi Warrants have the same terms as the Warrants issued to the investors, in connection with the Purchase Agreement.
Joint venture agreement, description																Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000 shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no assets or liabilities and has not started conducting any of its planned operations.
Common stock par value | (per share)																									$ 0.001	$ 0.001	$ 0.001						₪ 765
Additional paid in capital | $																									$ 34,491	$ 34,491	$ 30,272					$ 765
Change in fair value | $																									565		565
Chairman appointment agreement, description										The Company and Mr. Sieczkarek entered into a Chairman Agreement (the "Chairman Agreement") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("RSUs") and options to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards"). The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information, non-competition and non-solicitation.
Stock options granted during the vesting period | $										$ 29
Share-based expense related to RSU's | $										$ 185															$ 164
Stock issuance to consultant related, description																								The Company granted to its consultant options exercisable into 25,500 shares of Common Stock with an exercise price of $4.5 per share. The options will vest quarterly over a period of 36 months. The Company recognized $16 during the year ended December 31, 2018.
Company stock grants to its employee related, description												The Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019. The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement in December 2019, as of December 31, 2019, 3,600 options are outstanding and 18,000 were forfeited.
Vest options exercisable, term																									2 years 6 months
Contractual term of stock-based grants, description																									The Company and five representative companies and expected term of stock-based grants of 7 years.
Common stockholders amount | $																									$ 765
Common Stock [Member]
Issued shares of common stock																									900,000
Company stock grants to its employee related, description							The Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with an exercise price of $3.59 per share. The Company recognized $154 and $295 during the year ended December 31, 2019 and 2018, respectively.
Common stockholders amount | $																									$ 1
2012 Plan [Member
Future investment exercised, shares																									4,896	4,896
Common Stock available for future grant																									40,474	40,474
Shares issued																									4,896	4,896
2018 Plan [Member
Common stock shares issued																									435,053	435,053				2,500,000
Common Stock available for future grant																									967,178	967,178
Description of investments																									(i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.
Stock outstanding related, description																									Through December 31, 2019, 352,072 options to directors, officers and consultants are outstanding.
Restricted Stock Units (RSUs) [Member]
Future investment exercised, shares					25,300																								25,300		25,300
Share-based expense related to RSU's | $																									$ 104
Shares issued					25,300																								25,300		25,300
Stock issuance to consultant related, description				The Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.	The Company issued to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule: 25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.
Company stock grants to its employee related, description							The Company granted to its officers, directors and a consultant, 131,200 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of these RSUs issued was $471, and was recognized during the three months ended June 30, 2018.							1. To grant to each of Company's four directors 100,000 RSU's. The RSU's will vest quarterly over a period of 24 months. 2. To grant to each its officers (Company's Chief executive officer and to Company's Chief financial officer) 140,000 RSU's. The RSU's will vest quarterly over a period of 24 months.
Beneficial Owner [Member]
Ownership, percentage																	4.99%	4.99%
Investor [Member]
Ownership, percentage																	9.99%	9.99%
Liquidated damages to investors, description																	The Company shall pay to each investor cash equal to 2% of such investor's total purchase price on the dates of each deficiency and on the 30th day after such deficiencies until such deficiencies are cured, up to a maximum of 10% of the purchase price.
Mesodi [Member]
Warrant exercise price | ₪ / shares																										$ 0.16
Common stockholders amount | $																									$ 18
Rimon Gold And Fisher [Member]
Common stock shares issued																									2,816,196	2,816,196
Stock issuance to consultant related, description			the Company granted to one of its directors options exercisable into 30,000 shares of Common Stock with an exercise price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of share-based compensation expense during year ended December 31, 2019.
Preferred Class A [Member]
Converted instrument shares						336					336				60
Common stock value issued for services | $																											$ 440
Common stock shares issued for services																											440,000
Purchase agreement, description																		(i) 150 days following the date that all of the Common Stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, (ii) six months after the date that a non-affiliate investor under the Purchase Agreement may first sell securities purchased thereunder under Rule 144, (iii) 120 days following the listing of the Common Stock on a Qualified Market (as defined below) and (iv) the first trading day that the weighted average price of the Common Stock exceeds $5.00 per share for 10 consecutive trading days.
Series A Certificate of Designations [Member]
Converted instrument shares																		1,000
Preferred stock, dsignated																		1,350
Preferred stock designated stock | $																		$ 1,000
Shares of common stock, dividing | $																		$ 1,000
Conversion price | $ / shares																	$ 1.00	$ 1.00
Series A Certificate of Designations [Member] | Beneficial Owner [Member]
Ownership, percentage																	4.99%	4.99%
Series A Certificate of Designations [Member] | Investor [Member]
Ownership, percentage																	9.99%	9.99%
Private Placement [Member] | Preferred Class A [Member]
Purchase agreement, description																		(i) 3,100,000 shares of Common Stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of Common Stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also issued to the investors Series A Warrants to purchase an aggregate of 4,450,000 shares of Common Stock (equal to 100% of the shares of Common Stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)) (the "Series A Warrants"), and Series B Warrants (the "Series B Warrants", and together with the Series A Warrants, the "Warrants"), to purchase an aggregate of 4,450,000 shares of Common Stock (equal to 100% of the shares of Common Stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants have an exercise price of $1.10 per share, and the Series B Warrants have an exercise price of $1.00 per share
Two Service Providers [Member]
Common stock value issued for services | $																			$ 67,778	$ 24,306	$ 24,306
Common stock shares issued for services																			381								126
2016 Investment Right [Member]
Future investment exercised | $																									$ 853	$ 853
Future investment exercised, shares																									217,442	217,442
Shares of common stock, per share | ₪ / shares																												₪ 1.308
Shares issued																									217,442	217,442
2017 Investment Right [Member]
Future investment exercised | $																									$ 853	$ 853
Future investment exercised, shares																									427,048	427,048
Shares of common stock, per share | ₪ / shares																												₪ 1.332
Shares issued																									427,048	427,048
Warrant [Member]
Aggregate exercise price of warrants | $																									$ 292	$ 292
Common stock shares issued																									759,871	759,871
Issued shares of common stock																									144,168
Warrants exercised shares of common stock																									144,168
Common stockholders amount | $																									$ 15
Board of Directors [Member]
Reverse stock split, description								The Company announced a notice of special meeting of stockholders, according to which, a special meeting of the stockholders was held on February 19, 2018, for the purpose of considering to grant the Company’s Board of Directors (the “Board”) the authority, in its sole direction, to approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200.														The Company’s Board approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of 1-for-24 (the “Reverse Stock Split”).	The stockholders of the Company approved a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200 at any time prior to February 19, 2019, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion.